Camrelizumab
(Synonyms: 卡瑞利珠单抗; SHR-1210) 目录号 : GC62253
卡瑞利珠单抗（Camrelizumab, 也称为SHR-1210）是一种高亲和力、人源化IgG4-κ单克隆抗体。
Cas No.:1798286-48-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Camrelizumab (also known as SHR-1210) is a high-affinity, humanized IgG4-κ monoclonal antibody. It exhibits a strong binding affinity to PD-1, with a Kd of 3 nM, and effectively prevents the engagement of PD-1 with its ligand PD-L1, achieving an IC50 of 0.70 nM. Functioning as an anti-PD-1/PD-L1 therapeutic, Camrelizumab is valuable in oncology research and treatment, with applications in various malignancies such as non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), Hodgkin's lymphoma, and advanced hepatocellular carcinoma (HCC), among others[1][2].
Camrelizumab induced T-cell proliferation at an EC50 of 0.11 nM in peripheral blood mononuclear cells treated with tuberculin, and it induced the production of IFN-gamma at an EC50 of 0.38 nM in a similar assay measuring IFN-gamma secretion[2].
Camrelizumab (dosed at 3 mg/kg) and apatinib (dosed at 200 mg/kg and 100 mg/kg) exhibited tumor growth inhibition rates of 63.1% and 87.3%, respectively, in human PD-1 transgenic mice. Camrelizumab blocked the binding of PD-1 to its ligand PD-L1, which relieved the immune suppression in the tumor microenvironment, enhanced the activity of T cells, and thus improved the immune response against tumors[1].
References:
[1] Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191.
[2]Jason D Lickliter, et al. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther. 2020 Mar 18:14:1177-1189.
卡瑞利珠单抗（Camrelizumab, 也称为SHR-1210）是一种高亲和力、人源化IgG4-κ单克隆抗体。它对PD-1具有强烈的结合亲和力，Kd值为3 nM，并且有效阻止PD-1与其配体PD-L1的结合，IC50达到0.70 nM。作为一种抗PD-1/PD-L1治疗剂，卡瑞利珠单抗在肿瘤学研究和治疗中具有重要价值，适用于多种恶性肿瘤，如非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、霍奇金淋巴瘤和晚期肝细胞癌（HCC）等[1][2]。
卡瑞利珠单抗在结核菌素处理的外周血单核细胞中诱导T细胞增殖的EC50为0.11 nM，以及在测量IFN-gamma分泌的类似测定中，以0.38 nM的EC50诱导IFN-gamma的产生[2]。
卡瑞利珠单抗（剂量为3 mg/kg）与阿帕替尼（剂量为200 mg/kg和100 mg/kg）在人PD-1转基因小鼠中的肿瘤生长抑制率分别为63.1%和87.3%，卡瑞利珠单抗通过阻断PD-1与其配体PD-L1的结合，解除肿瘤微环境中的免疫抑制，增强T细胞的活性，从而提高对肿瘤的免疫反应[1]。
| Cell experiment [1]: | |
Cell lines | Peripheral blood mononuclear cells |
Preparation Method | Camrelizumab reconstituted in water and diluted in 5% dextrose to a final concentration of 0.11 nM/ 0.38 nM. |
Reaction Conditions | 0.11 nM/ 0.38 nM |
Applications | In the T-cell proliferation assay using peripheral blood mononuclear cells stimulated with tuberculin, Camrelizumab induced T-cell proliferation at an EC50 of 0.11 nM. In a similar assay measuring the secretion of IFN-gamma, Camrelizumab induced the production of IFN-gamma at an EC50 of 0.38 nM. |
| Animal experiment [2]: | |
Animal models | Human PD-1 transgenic mice |
Preparation Method | Camrelizumab was provided as a lyophilized (freeze-dried) powder; it had to be reconstituted with a specified volume of an appropriate solvent, such as sterile water or saline, to achieve the desired concentration for injection (3 mg/kg). |
Dosage form | 3 mg/kg, intravenous (iv) injection |
Applications | The combination of Camrelizumab (at a dosage of 3 mg/kg) with Apatinib (at dosages of 200 mg/kg and 100 mg/kg) resulted in tumor growth inhibition rates of 63.1% and 87.3%, respectively, in human PD-1 transgenic mice. |
References: [1] Jason D Lickliter, et al. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther. 2020 Mar 18:14:1177-1189. | |
| Cas No. | 1798286-48-2 | SDF | |
| 别名 | 卡瑞利珠单抗; SHR-1210 | ||
| 分子式 | 分子量 | ||
| 溶解度 | 储存条件 | -20°C, protect from light. | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet